Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lina Anthony

Critical Care Medicine Mesa, AZ Medical Doctor

NPI 1679522874 CMS profile 212259

3638 E Southern Ave Ste C108, Mesa, AZ 85206

Open in the dashboard

General payments

$6,351

251 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lina Anthony of Mesa, AZ is reported in the CMS Open Payments database as having received $6,351 across 251 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,349 52
2024 General $1,150 43
2023 General $1,510 50
2022 General $1,304 44
2021 General $967 58
2020 General $59 3
2019 General $12 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lina Anthony
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Lina Anthony were reported at $1,349. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Lina Anthony Critical Care Medicine median Middle half National median
2019 $12 $149 $51–$535 $163
2020 $59 $110 $30–$325 $114
2021 $967 $125 $34–$403 $132
2022 $1,304 $157 $49–$582 $149
2023 $1,510 $162 $56–$621 $160
2024 $1,150 $168 $53–$634 $164
2025 $1,349 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $722 10 payments
  2. GlaxoSmithKline, LLC. $645 38 payments
  3. United Therapeutics Corporation $496 20 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $423 21 payments
  5. Pulmonx Corporation $390 6 payments
  6. Actelion Pharmaceuticals US, Inc. $365 9 payments
  7. Mylan Specialty L.P. $262 4 payments
  8. Insmed, Inc. $220 10 payments
  9. Amgen Inc. $190 6 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $178 12 payments
  11. Other $2,459 115 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,263 247 payments
  2. Education $87 4 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $475 26 payments
  2. CHARTIS CATHETER $390 6 payments
  3. ZEPHYR ENDOBRONCHIAL VALVE $390 6 payments
  4. PULMONX CHARTIS TABLET CONSOLE $390 6 payments
  5. ZEPHYR DELIVERY CATHETER $390 6 payments
  6. OPSUMIT $365 9 payments
  7. YUPELRI $291 6 payments
  8. TYVASO $249 13 payments
  9. TEZSPIRE $244 3 payments
  10. UPTRAVI $242 4 payments
  11. Other $4,711 214 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

2,883

Median for Pulmonary Disease: 936

Drug cost

$1,665,795

Median for Pulmonary Disease: $487,987

Branded share of claims

72.7%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 42 $604,348
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 233 $219,950
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 185 $182,148
Breo Ellipta Fluticasone/Vilanterol Brand 224 $117,083
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 102 $71,643
Xolair Omalizumab Brand 27 $62,168
Symbicort Budesonide/Formoterol Fumarate Brand 191 $60,440
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 71 $49,907
Advair Hfa Fluticasone Propion/Salmeterol Brand 59 $41,299
Spiriva Respimat Tiotropium Bromide Brand 45 $36,096

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$263,226

Of which drugs: $95

Medicare patients

955

Average age 76

Services billed

3,642

532 women, 423 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 55%
Arthritis 55%
Ischemic heart disease 48%
Diabetes 32%
Chronic kidney disease 32%
Heart failure 30%
Atrial fibrillation 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg J7613 Office 153 160 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
YUPELRI
  • Mylan Specialty L.P. $144
$144 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $139
$139 — —
TYVASO
  • United Therapeutics Corporation $111
$111 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $100
$100 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $83
$83 185 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

251 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record